Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Johan Zelano

Showing results (41-50 of 152) with videos related to

Pageof 16
Sort By:
Pediatric Neurology|September 14, 2023
Corrigendum to "Selection and Continuation of Antiseizure Medication in Children With Epilepsy in Sweden From 2007 to 2020" Pediatric Neurology 144 (2023)(19-25)Samuel Håkansson, Ronny Wickström, Johan Zelano
Lakartidningen|May 23, 2018
[Classification of seizures and epilepsies]Johan Zelano, Tommy Stödberg, Torbjörn Tomson
Brain and Behavior|October 21, 2025
Demographic and Comorbidity Barriers to Therapy Revision in Epilepsy: A Population-Wide InvestigationAndré Idegård, David Larsson, Johan Zelano
The Lancet Regional Health. Europe|August 1, 2025
Trends in epilepsy mortality of three incidence cohorts across 2006-2023 in Sweden: a matched register-based studyJohan Zelano, André Idegård, David Larsson
Journal of Neurology, Neurosurgery, and Psychiatry|March 10, 2021
Post-traumatic epilepsy in adults: a nationwide register-based studyMarkus Karlander, Johan Ljungqvist, Johan Zelano
Seizure|December 3, 2014
Hypoglycemia and risk of seizures: a retrospective cross-sectional studyHalawa Imad, Johan Zelano, Eva Kumlien
Acta Neurologica Scandinavica|July 19, 2022
Temporal trends of epilepsy in multiple sclerosisZamzam Mahamud, Joachim Burman, Johan Zelano
Pediatric Neurology|April 28, 2023
Selection and Continuation of Antiseizure Medication in Children With Epilepsy in Sweden From 2007 to 2020Samuel Håkansson, Ronny Wickström, Johan Zelano
Multiple Sclerosis and Related Disorders|November 15, 2019
Prognostic impact of epilepsy in multiple sclerosisZamzam Mahamud, Joachim Burman, Johan Zelano
Epilepsia|July 10, 2025
Real-world retention of newer ASMs, including lacosamide and brivaracetam as first or second therapies in adult-onset epilepsyAndré Idegård, David Larsson, Johan Zelano
Pageof 16

Showing results (41-50 of 152) with videos related to

Sort By:
Pageof 16
Pediatric Neurology|September 14, 2023
Corrigendum to "Selection and Continuation of Antiseizure Medication in Children With Epilepsy in Sweden From 2007 to 2020" Pediatric Neurology 144 (2023)(19-25)Samuel Håkansson, Ronny Wickström, Johan Zelano
Lakartidningen|May 23, 2018
[Classification of seizures and epilepsies]Johan Zelano, Tommy Stödberg, Torbjörn Tomson
Brain and Behavior|October 21, 2025
Demographic and Comorbidity Barriers to Therapy Revision in Epilepsy: A Population-Wide InvestigationAndré Idegård, David Larsson, Johan Zelano
The Lancet Regional Health. Europe|August 1, 2025
Trends in epilepsy mortality of three incidence cohorts across 2006-2023 in Sweden: a matched register-based studyJohan Zelano, André Idegård, David Larsson
Journal of Neurology, Neurosurgery, and Psychiatry|March 10, 2021
Post-traumatic epilepsy in adults: a nationwide register-based studyMarkus Karlander, Johan Ljungqvist, Johan Zelano
Seizure|December 3, 2014
Hypoglycemia and risk of seizures: a retrospective cross-sectional studyHalawa Imad, Johan Zelano, Eva Kumlien
Acta Neurologica Scandinavica|July 19, 2022
Temporal trends of epilepsy in multiple sclerosisZamzam Mahamud, Joachim Burman, Johan Zelano
Pediatric Neurology|April 28, 2023
Selection and Continuation of Antiseizure Medication in Children With Epilepsy in Sweden From 2007 to 2020Samuel Håkansson, Ronny Wickström, Johan Zelano
Multiple Sclerosis and Related Disorders|November 15, 2019
Prognostic impact of epilepsy in multiple sclerosisZamzam Mahamud, Joachim Burman, Johan Zelano
Epilepsia|July 10, 2025
Real-world retention of newer ASMs, including lacosamide and brivaracetam as first or second therapies in adult-onset epilepsyAndré Idegård, David Larsson, Johan Zelano
Pageof 16